Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Department of Radiation Oncology, Kobe Proton Center, Kobe, Japan.
Cancer Med. 2022 Mar;11(6):1502-1510. doi: 10.1002/cam4.4553. Epub 2022 Feb 9.
This study aimed to evaluate acute toxicities associated with irradiation between the X-CSI (photon beam craniospinal irradiation) and P-CSI (proton beam craniospinal irradiation) groups in children with brain tumors.
Sixty-two consecutive patients who received initial craniospinal irradiation (CSI) for brain tumors in our center between January 1, 2011 and May 31, 2021, were included in the study. Acute toxicities were retrospectively evaluated during CSI using Common Terminology Criteria for Adverse Events version 5.0. Maximum grades of fatigue, headache, insomnia, nausea, vomiting, dermatitis, constipation, abdominal pain, oropharyngeal mucositis, and hematological toxicities were evaluated.
Thirty-six patients received X-CSI, and 26 patients received P-CSI. The median dose of CSI was 18.0 Gy in the X-CSI group and 23.4 Gy (relative biological effectiveness) in the P-CSI group (p < 0.001). The P-CSI group had a lower incidence of more than grade 2 nausea (11.5% vs. 69.4%, p = 0.008) and vomiting (7.7% vs. 38.8%, p < 0.001), compared with the X-CSI group. Multivariate logistic regression analysis with adjustments for potential confounding factors of doses of CSI showed that proton radiation therapy was associated with a marked reduced risk of more than grade 2 nausea and vomiting during CSI (adjusted odds ratio, 0.050; 95% confidential interval, 0.011-0.24; p < 0.001).
The present study suggests that P-CSI reduces the acute gastrointestinal toxicities associated with irradiation.
本研究旨在评估光子束颅脊髓照射(X-CSI)和质子束颅脊髓照射(P-CSI)两组儿童脑瘤患者放疗相关的急性毒性。
本研究纳入了 2011 年 1 月 1 日至 2021 年 5 月 31 日在本中心接受初始颅脊髓照射(CSI)治疗的 62 例连续脑肿瘤患者。使用不良事件通用术语标准 5.0 版回顾性评估 CSI 期间的急性毒性。评估了疲劳、头痛、失眠、恶心、呕吐、皮炎、便秘、腹痛、口咽黏膜炎和血液学毒性的最大等级。
36 例患者接受 X-CSI,26 例患者接受 P-CSI。X-CSI 组 CSI 的中位剂量为 18.0 Gy,P-CSI 组为 23.4 Gy(相对生物效应)(p < 0.001)。与 X-CSI 组相比,P-CSI 组 2 级以上恶心(11.5% vs. 69.4%,p = 0.008)和呕吐(7.7% vs. 38.8%,p < 0.001)的发生率较低。在调整 CSI 剂量等潜在混杂因素的多变量逻辑回归分析中,质子放射治疗与 CSI 期间 2 级以上恶心和呕吐的风险显著降低相关(调整后的优势比,0.050;95%置信区间,0.011-0.24;p < 0.001)。
本研究表明,P-CSI 可降低放疗相关的急性胃肠道毒性。